<?xml version="1.0" encoding="UTF-8"?>
<p id="p0065">
 <bold>For hydroxychloroquine sulfate:</bold> an open-label, non-randomized clinical trial
 <xref rid="bib18" ref-type="bibr">
  <sup>18</sup>
 </xref> suggested, compared with the rate of viral nucleic acid turning negative of control group (12.5%), combination of hydroxychloroquine sulfate and azithromycin (100%) and monotherapy of hydroxychloroquine sulfate (57.1%) significantly improved the rate of viral nucleic acid turning negative (P &lt; 0.001). The effect of hydroxychloroquine sulfate is reinforced by azithromycin. And such combination may both act as an antiviral therapy against SARS-CoV-2 and prevent bacterial super-infections. However, a prospective study
 <xref rid="bib19" ref-type="bibr">
  <sup>19</sup>
 </xref> showed that, for patients with moderate COVID-19, the effect on the rate and the time of viral nucleic acid turning negative were not significant.
</p>
